Geri Pride: Feasibility Pilot of a Group Intervention for Older Veterans
Geri Pride: an Adapted Intervention to Support Healthy Aging of Sexual and Gender Minority Veterans
2 other identifiers
interventional
60
1 country
4
Brief Summary
There are over one million Veterans who identify as lesbian, gay, bisexual, (LGB) or a related identity. Older LGB Veterans face unique hurdles as they age, including stress, anxiety, heart disease, cancer, decreased ability to perform activities of daily living, delayed care, and increased likelihood of entering a nursing home. Sparse social networks and limited access to aging resources are common for LGB Veterans and contribute to adverse outcomes. The proposed study will partner with older Veterans to adapt and test a virtual structured group that promotes healthy aging, self-acceptance, and connection to health-related resources. This study aims to improve Veterans' health and well-being through increased resilience, positive healthcare engagement, and access to resources that support older Veterans' needs. There are currently no other VA programs designed to address the unmet needs of older LGB Veterans. By learning more about how to serve subgroups of Veterans more effectively, this study will also improve outcomes for all older Veterans and their care partners.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2027
Typical duration for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 1, 2026
CompletedFirst Posted
Study publicly available on registry
September 21, 2026
CompletedStudy Start
First participant enrolled
July 1, 2027
ExpectedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2030
Study Completion
Last participant's last visit for all outcomes
July 31, 2030
September 21, 2026
September 1, 2026
2.8 years
September 1, 2026
September 17, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Participant Retention in the Intervention (Feasibility Indicator)
The primary indicator of intervention feasibility will be retention rate, operationalized as the % of enrolled participants who complete the intervention as tracked on attendance logs (observational data). Feasible retention in this multi-session psychosocial intervention is set at \>60% given anticipated intervention duration, prior trials with the parent intervention, and population comorbidities.
Active intervention-delivery period
Generalized Anxiety Disorder Score (GAD-7)
Symptoms of anxiety will be assessed using a 7-item self-report measure used frequently in clinical care settings within VHA. It will be completed by Veterans before and after the group.
Pre/Post Measures will be collected within approximately 1 month before the first session, and within 1 month of the last session. Time between pre and post measures will be approximately 4-6 months apart.
Secondary Outcomes (1)
Patient Health Questionnaire (PHQ-9)
Pre/Post Measures will be collected within approximately 1 month before the first session, and within 1 month of the last session. Time between pre and post measures will be approximately 4-6 months apart.
Study Arms (1)
Intervention Group
EXPERIMENTALManualized, structured, health promotion group delivered over tele-health or in a hybrid format.
Interventions
A structured, health promotion intervention adapted from the VA Pride in All Who Served program that covers a different topic each week related to healthy aging, internalized stress, what matters most/goals of care, social connections and care networks, VA and community resources, and other topics that promote well-being.
Eligibility Criteria
You may qualify if:
- Meets Pride in All Who Served (PAWS) clinical care service delivery screening criteria (e.g., identify as lesbian, gay, bisexual (LGB) or related identity, not experiencing acute symptoms that prevent meaningful participation in group-delivered care, able to access clinical care at a partnering site)
- Cognitively able to provide consent to participate in research
- years or older at the time of enrollment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama, 35404-5015, United States
Ralph H. Johnson VA Medical Center, Charleston, SC
Charleston, South Carolina, 29401-5703, United States
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Dallas, Texas, 75216-7167, United States
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, 84148-0001, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Michelle Marie Hilgeman, PhD
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Masking Details
- Not applicable for this single group feasibility pilot study.
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 1, 2026
First Posted
September 21, 2026
Study Start (Estimated)
July 1, 2027
Primary Completion (Estimated)
April 1, 2030
Study Completion (Estimated)
July 31, 2030
Last Updated
September 21, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share